GlassScriptPhysician profile
Kierston Holifield
NPI 1598916272
$4,261.47
in general payments reported to CMS, 2019-2025
29 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $524 · 2023: $604 · 2024: $1,703 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.97 |
| Education | $463.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.56 | 2023-2025 | |
| Medtronic, INC. | $508.69 | 2022-2024 | Intellis Adaptivestim, Accurian |
| Dermavant Sciences, INC. | $442.99 | 2024 | Vtama |
| Vertos Medical, INC. | $316.40 | 2021-2022 | |
| Janssen Biotech, INC. | $309.67 | 2023-2025 | Tremfya |
| Pfizer INC. | $286.28 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $200.01 | 2024-2025 | |
| Abbott Laboratories | $177.13 | 2023-2024 | Proclaim, Eterna |
| Janssen Scientific Affairs, LLC | $116.54 | 2024 | Tremfya |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Incyte Corporation | $99.59 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $96.48 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $92.58 | 2023-2025 | |
| Ucb, INC. | $76.46 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $67.83 | 2024-2025 | Taltz, Ebglyss, Olumiant |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $65.42 | 2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $61.45 | 2024 | Dupixent |
| Revance Therapeutics, INC. | $59.21 | 2025 | Daxxify |
| Nevro Corp. | $56.59 | 2021 | |
| Galderma Laboratories, L.P. | $56.27 | 2024-2025 | Aklief, Nemluvio |
| Amgen INC. | $44.59 | 2024-2025 | Otezla, Otezla |
| Allergan, INC. | $41.38 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.09 | 2023-2024 | Duobrii, Arazlo, Cabtreo |
| Novartis Pharmaceuticals Corporation | $29.18 | 2025 | |
| Organon LLC | $22.41 | 2025 | Vtama |
| Painteq LLC | $22.03 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.87 | 2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $16.71 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kierston Holifield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.